---
layout: post
title: New Drug Approvals 2012 - Pt. XXV - Tofacitinib citrate (XELJANZ®)
date: '2012-11-18T06:58:00.001Z'
author: Ramesh
tags:
- Small Molecule Drugs
- Kinase inhibitor
- Black Box Warning Drugs
- 2012 New Drugs
modified_time: '2012-11-18T06:58:42.583Z'
thumbnail: http://3.bp.blogspot.com/-pgCebC4NOS4/UKS-mBttvpI/AAAAAAAAAAQ/Z_ef3l3VeDA/s72-c/Screen+Shot+2012-11-15+at+10.04.50.png
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-1262293158293120450
blogger_orig_url: http://chembl.blogspot.com/2012/11/new-drug-approvals-2012-pt-xxv.html
---

<div dir="ltr" style="text-align: left;" trbidi="on">
<div class="separator" style="clear: both; text-align: center;">
</div>
<div class="separator" style="clear: both; text-align: center;">
</div>
<br />
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://mms.businesswire.com/bwapps/mediaserver/ViewMedia?mgid=345067&amp;vid=4" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="136" src="http://mms.businesswire.com/bwapps/mediaserver/ViewMedia?mgid=345067&amp;vid=4" width="320" /></a></div>
<div class="separator" style="clear: both; text-align: center;">
</div>
<div class="separator" style="clear: both; text-align: center;">
</div>
<div class="separator" style="clear: both; text-align: center;">
</div>
<div class="separator" style="clear: both; text-align: center;">
</div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://www.ebi.ac.uk/chembltools/autoiconlarge/1,1,0,2,0,0,1,0,1" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="37" src="https://www.ebi.ac.uk/chembltools/autoiconlarge/1,1,0,2,0,0,1,0,1" width="320" /></a></div>
<span class="Apple-style-span" style="color: #333333; font-family: Arial, Helvetica, 'Nimbus Sans L', sans-serif;"><span class="Apple-style-span"><span class="Apple-style-span" style="font-size: 14px; line-height: 19px;"><br />
</span></span></span> <br />
<div style="text-align: justify;">
<span style="font-family: inherit;"><span class="Apple-style-span" style="line-height: 19px;"><span class="Apple-style-span" style="color: #333333;">On November 6, the&nbsp;</span><span class="Apple-style-span" style="color: #333333;">FDA approved</span>&nbsp;<a href="http://en.wikipedia.org/wiki/Tofacitinib" target="_blank">T</a><span class="Apple-style-span" style="color: #333333;"><a href="http://en.wikipedia.org/wiki/Tofacitinib" target="_blank">ofacitinib</a>&nbsp;citrate (Trade Name:&nbsp;</span></span><span class="Apple-style-span" style="line-height: 19px;"><a href="http://www.xeljanz.com/" target="_blank">XELJANZ®</a>; Research code: CP-690550, ChEMBL :&nbsp;<a href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL221959" target="_blank">CHEMBL221959</a>, PubChem:&nbsp;<a href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=9926791" target="_blank">CID9926791</a>, DrugBank:&nbsp;<a href="http://www.drugbank.ca/drugs/DB08183" target="_blank">DB08183</a>, ChemSpider:&nbsp;<a href="http://www.chemspider.com/Chemical-Structure.8102425" target="_blank">8102425</a></span><span class="Apple-style-span" style="line-height: 19px;">)</span><span class="Apple-style-span" style="color: #333333; line-height: 19px;">&nbsp;to treat moderately to severely active&nbsp;<a href="http://en.wikipedia.org/wiki/Rheumatoid_arthritis" target="_blank">Rheumatoid Arthritis</a>&nbsp;(RA). It is orally administered and may be used as monotherapy agent or in combination of non-biologic&nbsp;<a href="http://en.wikipedia.org/wiki/DMARD" target="_blank">DMARDs</a>. About 1% of the world-wide population is affected by&nbsp;</span><span class="Apple-style-span" style="color: #333333; line-height: 19px;">rheumatoid arthritis</span><span class="Apple-style-span" style="color: #333333; line-height: 19px;">.</span><span class="Apple-style-span" style="color: #333333; line-height: 19px;">&nbsp;RA affects predominantly women (</span><span class="Apple-style-span" style="color: #333333; line-height: 19px;">three times more susceptible than men</span><span class="Apple-style-span" style="color: #333333; line-height: 19px;">) and is more frequent between ages 40 and 50, but people of any age can be affected</span><span class="Apple-style-span" style="color: #333333; line-height: 19px;">.</span></span></div>
<div style="text-align: justify;">
<span style="font-family: inherit;"><span class="Apple-style-span" style="color: #333333; line-height: 19px;"><br />
</span> </span></div>
<div style="text-align: justify;">
<div style="text-align: justify;">
<span style="font-family: inherit;"><span class="Apple-style-span" style="color: #333333; line-height: 19px;">Other approved drugs in this commercially competitive sector include&nbsp;<a href="http://en.wikipedia.org/wiki/Adalimumab" target="_blank">Adalimumab</a> (Trade Name:</span><span class="Apple-style-span">&nbsp;</span><span class="Apple-style-span" style="color: #333333; line-height: 19px;"><a href="http://www.humira.com/" target="_blank">Humira</a>, ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1201580" target="_blank">CHEMBL1201580</a>, DrugBank: <a href="http://www.drugbank.ca/drugs/DB00051" target="_blank">DB00051</a>)</span><span class="Apple-style-span" style="color: #333333; line-height: 19px;">, <a href="http://en.wikipedia.org/wiki/Etanercept" target="_blank">Etanercept</a> (Trade Name:&nbsp;</span><span class="Apple-style-span" style="color: #333333; line-height: 19px;"><a href="http://www.enbrel.com/index.jspx" target="_blank">Enbrel</a>,&nbsp;</span><span class="Apple-style-span" style="color: #333333; line-height: 19px;">ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1201572" target="_blank">CHEMBL1201572</a>, DrugBank: <a href="http://www.drugbank.ca/drugs/DB00005" target="_blank">DB00005</a>)</span><span class="Apple-style-span" style="color: #333333; line-height: 19px;">, Infliximab (Trade Name:&nbsp;<a href="http://www.remicade.com/" target="_blank">Remicade</a>, ChEMBL: <a href="https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL1201581" target="_blank">CHEMBL1201581</a>, DrugBank: <a href="http://www.drugbank.ca/drugs/DB00065" target="_blank">DB00065</a>).</span></span></div>
</div>
<div style="text-align: justify;">
<span class="Apple-style-span" style="color: #333333; font-family: Arial, Helvetica, 'Nimbus Sans L', sans-serif; font-size: 14px; line-height: 19px;"><br />
</span></div>
<div class="separator" style="clear: both; text-align: center;">
</div>
<div class="separator" style="clear: both; text-align: center;">
<a href="http://3.bp.blogspot.com/-pgCebC4NOS4/UKS-mBttvpI/AAAAAAAAAAQ/Z_ef3l3VeDA/s1600/Screen+Shot+2012-11-15+at+10.04.50.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="320" src="http://3.bp.blogspot.com/-pgCebC4NOS4/UKS-mBttvpI/AAAAAAAAAAQ/Z_ef3l3VeDA/s320/Screen+Shot+2012-11-15+at+10.04.50.png" width="208" /></a></div>
<br />
<div style="text-align: justify;">
<div style="text-align: left;">
<span class="Apple-style-span" style="color: #333333; font-family: inherit; line-height: 19px;"><b>IUPAC Name:</b>&nbsp;3-(4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile</span></div>
<div style="text-align: left;">
<span class="Apple-style-span" style="color: #333333; font-family: inherit; line-height: 19px;"><b>Canionical Smiles:</b> C[C@@H]1CCN(C[C@@H]1N(C)c2ncnc3[nH]ccc23)C(=O)CC#N</span></div>
<div style="text-align: left;">
<span class="Apple-style-span" style="color: #333333; font-family: inherit; line-height: 19px;"><b>Standard InChi</b> :&nbsp;InChI=1S/C16H20N6O/c1-11-5-8-22(14(23)3-6-17)9-13(11)21(2)16-12-4-7-18-15(12)19-10-20-16/h4,7,10-11,13H,3,5,8-9H2,1-2H3,(H,18,19,20)/t11-,13+/m1/s1</span></div>
<div style="text-align: left;">
<span class="Apple-style-span" style="color: #333333; font-family: inherit; line-height: 19px;"><b>Standard InChi Key</b>:&nbsp;UJLAWZDWDVHWOW-YPMHNXCESA-N</span></div>
<div style="text-align: left;">
<span class="Apple-style-span" style="color: #333333;"><span class="Apple-style-span" style="font-family: inherit; line-height: 19px;"><br /></span></span></div>
</div>
<div style="text-align: justify;">
<a href="http://www.blogger.com/blogger.g?blogID=2546008714740235720" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"></a><span class="Apple-style-span" style="color: #333333; font-family: inherit; line-height: 19px;">XELJANZ is the citrate salt of tofacitinib which is an inhibitor of Janus Kinase (<a href="http://en.wikipedia.org/wiki/Janus_kinase" target="_blank">JAK</a>), an intracellular tyrosine kinase which transmit signals from cytokine or growth factor-receptor interactions on the cell membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signalling pathway JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression. JAK-STAT system is a major signalling alternative to the <a href="http://en.wikipedia.org/wiki/Second_messenger_system" target="_blank">secondary messenger</a> system.</span><br />
<span class="Apple-style-span" style="color: #333333; font-family: Arial, Helvetica, 'Nimbus Sans L', sans-serif; font-size: 14px; line-height: 19px;"><br /></span></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="http://mpnforum.files.wordpress.com/2012/07/jak-stat-pathway1.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="320" src="http://mpnforum.files.wordpress.com/2012/07/jak-stat-pathway1.jpg" width="257" /></a></div>
<div style="text-align: justify;">
<span class="Apple-style-span" style="color: #333333; font-family: Arial, Helvetica, 'Nimbus Sans L', sans-serif; font-size: 14px; line-height: 19px;"><br /></span>
<span style="font-family: inherit;"><span class="Apple-style-span" style="color: #333333; line-height: 19px;">XELJANZ is specifically designed to inhibit the JAK pathways, which are signalling pathways inside the cell that play an important role in the inflammation involved in RA. Tofacitinib modulates the signalling pathway and prevents the phosphorylation and activation of STATs. JAK enzymes transmit cytokine signalling through pairing of JAKs (e.g., JAK1/JAK2, JAK1/JAK3, JAK1/TyK2, JAK2/JAK2).&nbsp;</span><span class="Apple-style-span" style="color: #333333; line-height: 19px;">Tofacitinib has in vitro activities against JAK1/JAK2, JAK1/JAK3 and JAK2/JAK2 combinations.</span></span><br />
<span style="font-family: inherit;"><span class="Apple-style-span" style="color: #333333; line-height: 19px;"><br /></span>
<span class="Apple-style-span" style="color: #333333; line-height: 19px;">The picture on left is&nbsp;</span><span class="Apple-style-span" style="color: #333333; line-height: 19px;">PDB entry:&nbsp;<a href="http://www.ebi.ac.uk/pdbe-srv/view/entry/3lxn/summary" target="_blank">3lxn</a>&nbsp;for&nbsp;</span><span class="Apple-style-span" style="color: #333333; line-height: 19px;">crystal structure for&nbsp;<a href="http://www.uniprot.org/uniprot/P52333" target="_blank">TYK2</a>&nbsp;(in Red)&nbsp;</span><span class="Apple-style-span" style="color: #333333; line-height: 19px;">with CP-690550 (in Blue/Green) and the picture on right is </span><span class="Apple-style-span" style="color: #333333; line-height: 19px;">PDBe entry:&nbsp;<a href="http://www.ebi.ac.uk/pdbe-srv/view/entry/3lxk/summary" target="_blank">3lxk</a>&nbsp;for crystal structure for&nbsp;<a href="http://www.uniprot.org/uniprot/P29597" target="_blank">JAK3</a>&nbsp;(in Red)&nbsp;</span><span class="Apple-style-span" style="color: #333333; line-height: 19px;">with CP-690550 (in Blue/Green).</span></span><br />
<span class="Apple-style-span" style="color: #333333; font-family: Arial, Helvetica, 'Nimbus Sans L', sans-serif; font-size: 14px; line-height: 19px;"><br /></span>
<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://4.bp.blogspot.com/-2JnWnDWT5Zo/UKTgDqtw5VI/AAAAAAAAACk/8F38AGTaGXw/s1600/PicMonkey+Collage.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="204" src="http://4.bp.blogspot.com/-2JnWnDWT5Zo/UKTgDqtw5VI/AAAAAAAAACk/8F38AGTaGXw/s640/PicMonkey+Collage.jpg" width="640" /></a></div>
<span class="Apple-style-span" style="color: #333333; font-family: Arial, Helvetica, 'Nimbus Sans L', sans-serif; font-size: 14px; line-height: 19px;"><br /></span>

<span style="font-family: inherit;"><span class="Apple-style-span" style="color: #333333; line-height: 19px;">Recommended dosage is 5 mg orally. It has an apparent volume of distribution of 87 L and protein binding to the drug is approximately 40%, and it's bioavailability is 74% with elimination half-life of approximately 3 hrs.&nbsp;</span><span class="Apple-style-span" style="color: #333333;"><span class="Apple-style-span" style="line-height: 19px;">Metabolism of Tofacitinb is majorly mediated by Cytochrome P450 3A4 (<a href="http://www.uniprot.org/uniprot/P08684" target="_blank">CYP3A4</a></span></span><span class="Apple-style-span" style="color: #333333; line-height: 19px;">) and minor contribution from Cytochrome P450 2C19 (</span><span class="Apple-style-span" style="color: #333333; line-height: 19px;"><a href="http://www.uniprot.org/uniprot/P33261" target="_blank">CYP2C19</a></span><span class="Apple-style-span" style="color: #333333; line-height: 19px;">). Clearance is estimated to be 70% hepatic, 30% renal.</span></span></div>
<div style="text-align: justify;">
</div>
<div style="text-align: justify;">
<div class="separator" style="clear: both; text-align: center;">
</div>
<span style="font-family: inherit;"><span class="Apple-style-span" style="color: #333333; line-height: 19px;"><br />
</span> <span class="Apple-style-span" style="color: #333333; line-height: 19px;">Full prescribing information can be found&nbsp;<a href="http://labeling.pfizer.com/ShowLabeling.aspx?id=959" target="_blank">here</a>.</span></span><br />
<span style="font-family: inherit;"><span class="Apple-style-span" style="color: #333333; line-height: 19px;"><br />
</span> <span class="Apple-style-span" style="color: #333333;"><span class="Apple-style-span" style="line-height: 19px;">License holder is <a href="http://www.pfizer.com/home/" target="_blank">Pfizer</a> and product website is <a href="http://www.xeljanz.com/">www.xeljanz.com</a>.</span></span></span></div>
</div>
